How to Prepare Technical Documentation for Overseas Registration of Medical Dressings

How to Prepare Technical Documentation for Overseas Registration of Medical Dressings

Technical documentation for overseas registration of medical dressings cannot simply be copied from domestic Chinese registration files or replicated using a single-country template. Companies must first determine the regulatory classification of the product in the target country, identify the risk class and registration pathway, and then assess whether existing NMPA, CE, FDA, ISO 13485, or MDSAP documentation can be reused. The core technical file includes product description, raw material and supplier information, manufacturing process and validation, performance testing, biocompatibility, risk management, clinical evaluation or clinical evidence, labeling and instructions for use, sterilization validation, and stability data. Acceptance of the file depends on completeness of the evidence chain, alignment with local technical review logic, and submission and deficiency responses conducted by a local agent or authorized representative.

The most common mistake companies make is neglecting localization differences. For example, a risk management report formatted for China or the EU may be submitted directly to Southeast Asian or Middle Eastern countries, or the local regulatory classification of dressing products may be misinterpreted, leading to an incorrect registration pathway. When preparing documentation, companies should first establish a technical documentation index, clearly identify which documents can be reused and which require localization conversion, and reserve at least 20% of project time and budget for communication with local agents, notarized translations, and post-market maintenance. In addition, certificate control, change management, and renewal responsibilities affect the product's continued market availability and should not be overlooked in favor of initial registration only.

Applicable Scenarios and Core Questions

Medical dressings are a common medical device category, including wound dressings, wound care dressings, post-surgical dressings, antimicrobial dressings, hydrocolloid dressings, and alginate dressings. When preparing to enter overseas markets, the first question a company must answer is: Does the product fall under the medical device definition in the target country? The answer is not uniform. For instance, some dressings are managed as Class II devices in China, but in a Southeast Asian country they may be classified as Class I or Class II, or even considered everyday consumer products outside medical device regulation.

Another core question is how the intended use is defined. For the same dressing, if it is claimed for chronic wound management, the risk class is generally higher than for a dressing intended only for superficial abrasions. This claim affects the clinical evaluation, performance testing, and labeling content in the technical file. If companies do not clearly define intended use early in the project, they often have to adjust the technical file later, causing registration delays.

Before preparing technical documentation, companies should clarify the market scope of the registration. If registering in GHWP member countries or in multiple countries across Southeast Asia, the Middle East, or Latin America, it is essential to understand each country's requirements for technical file format and language. Some countries accept English-only files, some require local language translation, and others require letters and documents issued by a local agent.

A common misconception is to first collect all documents and then consider how to translate and submit them. A more reasonable approach is to first conduct regulatory research on the target country, determine classification, pathway, and supporting document requirements, and then perform a gap analysis against existing documentation.

Registration Decision Logic

Step 1: Determine whether the product falls within the medical device regulatory scope of the target country. For medical dressings, companies need to review the target country's medical device definition to confirm that the product does not fall into pharmaceutical, cosmetic, or general consumer categories.

Step 2: Determine the risk class and registration pathway. Class I dressings typically undergo self-declaration with required document submission, while Class II and higher dressings require the registrant to submit a technical file for regulatory review. Requirements for each risk class vary significantly by country. For example, some Middle Eastern countries require even Class I products to be submitted through a local agent and undergo formal review.

Step 3: Determine the applicant entity. The applicant is usually a legal company registered in the target country, so a local agent or authorized representative must be appointed. The authorized representative is responsible for communicating with regulatory authorities, receiving deficiency letters, maintaining technical files, reporting adverse events, and bearing ongoing compliance obligations during the certificate validity period.

Step 4: Assess whether existing NMPA, CE, FDA, ISO 13485, MDSAP, or other market documentation can be reused. The degree of reuse depends on document type, evidence standards, and language. Physical performance testing, biocompatibility testing, stability testing, and similar data are usually reusable, but clinical evaluation or clinical evidence often requires reference to target-country population data or adjustment of the argumentation logic.

Step 5: Confirm technical file, performance validation, risk management, clinical evaluation or clinical evidence, labeling and instructions, local agent, authorized representative, and post-market maintenance requirements. Companies should establish a registration timeline with clear milestones for each phase to avoid treating deficiency responses as an afterthought.

Documentation and Evidence

The technical file typically includes basic product information, raw material and supplier information, manufacturing process and process validation, product performance testing, biocompatibility, risk management, sterilization validation and shelf-life validation, stability reports, clinical evaluation or clinical evidence, label and instruction draft, packaging labeling, software validation (if applicable), and quality management system documents.

The product description section should accurately state the model, structure and composition, mechanism of action, intended user, target population, environment of use, and method of use. It is not enough to describe the product; differences from similar products and whether those differences affect safety and effectiveness must also be explained.

Raw material and supplier information should provide source, quality standards, declarations of conformity, and biological safety data for critical raw materials. If animal-derived or human-tissue-derived materials are involved, additional validation of inactivation of infectious agents and proof of origin are required.

Manufacturing process validation should include process flow diagrams, critical process parameters, validation reports, cleaning confirmation, and environmental monitoring data. If products are manufactured in cleanrooms, cleanroom class and microbial monitoring records should be provided.

Performance testing should cover physical, chemical, and microbiological properties. For wound dressings, common test items include appearance and dimensions, liquid absorption, water vapor transmission rate, adhesion peel strength, bacterial barrier, pH, heavy metal content, sterility, and microbial limits. Companies should confirm whether test method standards are accepted by the target country or whether additional local standard reports are required.

Biocompatibility evaluation should follow the ISO 10993 series. Based on contact time and nature, tests such as cytotoxicity, sensitization, irritation, intracutaneous reactivity, and systemic toxicity should be selected. Even if CE or FDA has accepted biocompatibility reports, some countries still require reports based on local product standards or additional testing.

The risk management report should be based on ISO 14971 and include a complete risk management document with risk analysis, risk evaluation, risk control measures, residual risk evaluation, and a risk management report. Do not submit only a risk table; there must be full traceability from design input to verification and validation.

The clinical evaluation part can be divided into direct clinical evidence and literature-based argumentation. For most low-risk dressings, peer-reviewed literature and equivalent product data can be cited. For dressings claiming special effects such as antimicrobial or wound healing promotion, clinical trial reports or real-world data may be required.

Labels and instructions must comply with target country language requirements and include the certificate holder information, instructions for use, warnings and precautions, storage conditions, expiry date, batch number, and CE/FDA marks where applicable. For multi-country export, multilingual versions should be designed, and label information must be consistent with registration content.

Common Mistakes

• Mistake 1: Failing to determine the classification in the target country and simply applying the Chinese or EU classification, leading to wrong registration pathway, wasted time, and money.
• Mistake 2: Copying NMPA or CE submission documents without local adaptation. Many countries require document formats that comply with local specifications and do not accept direct submission of other systems.
• Mistake 3: Ignoring the statutory responsibilities of the local agent. Some companies only obtain a mailing address in the target country without a formal authorized representative agreement, delaying deficiency responses.
• Mistake 4: Insufficient clinical evaluation evidence. For dressings claiming “wound healing promotion,” submitting only laboratory data without clinical evidence often leads to rejection during review.
• Mistake 5: Inaccurate translation of labels and instructions. Translation errors of intended use in the EU may alter risk class; Middle Eastern and Latin American markets also require local-language instructions, and careless translation can lead to missing safety warnings.
• Mistake 6: Missing post-market surveillance and adverse event reporting documents. Some countries require a post-market surveillance plan as part of the technical file; absence is viewed as a system deficiency.
• Mistake 7: Unclear certificate control. The company should hold the registration certificate, but it is often held in the name of the local agent or the electronic certificate is kept by the agent. If certificate ownership and change rights are not defined in the agency agreement, transferring to a new authorized representative becomes very difficult.
• Mistake 8: Lack of technical file version control. Overseas registration documents must be consistent with the quality management system. If product design or process changes are not reflected in registration documents, regulatory risk arises.

Company Preparation Checklist

• Conduct regulatory and classification research for the target country; prepare a registration pathway memo and risk class justification.
• Define intended use and indications; draft product labels and instruction for use accordingly.
• Appoint or contract a local authorized representative; sign a formal agency agreement that clearly defines certificate ownership, change notification, deficiency response, and post-market responsibilities.
• Create a gap analysis table against the target country's requirements or a common technical document list.
• Collect corporate qualification documents: business license, medical device registration/filing certificate, CE certificate, FDA 510(k), ISO 13485 certificate, MDSAP certificate, etc.
• Compile raw material supplier data, declarations of conformity, ISO 10993 biocompatibility reports, product performance test reports, sterilization validation reports, and shelf-life validation protocols and reports.
• Develop risk management documents and clinical evaluation materials; consult professional firms when necessary to ensure a complete evidence chain.
• Create a localization translation plan for labels and instructions; arrange internal review and regulatory review.
• Design adverse event reporting and post-market surveillance procedures; save vigilance document templates; establish a complaint handling process in cooperation with the local agent.
• Plan budget and timeline, including deficiency response period, translation notarization, and local agent communication time in project milestones.
• Prepare the technical file index and quality system documents to ensure traceability and updateability.

AIMEILI’s Perspective

Companies often underestimate the weight of “localization.” Many believe that if CE or FDA has approved the product, the same documentation can be translated and submitted to GHWP member countries, the Middle East, or Latin America. In reality, technical files differ not only in language but also in regulatory framework, classification, evidence preferences, and format requirements. For example, the EU requires a complete risk management document, some Southeast Asian countries are more concerned with production environment validation and storage stability, and some Middle Eastern countries require original sterilization validation documents and do not accept copies.

Three actions should be prioritized at the project outset: first, clearly define product intended use and indications; second, confirm target-country classification and registration pathway; third, sign a formal agreement with a local agent that defines responsibilities in document preparation, deficiency responses, change reporting, and renewal. Do not save costs by using a local mailbox service provider with no registration experience.

What documentation can be reused? Physical performance testing, biocompatibility testing, shelf-life/stability validation, sterilization validation, and ISO 13485 system certificates. Reports obtained under international standards or commonly accepted methods are accepted by most countries. What must be localized? Labels and instructions, clinical evaluation or clinical argumentation logic, portions of the risk management report that refer to local regulations and standards, and country-specific registration forms and declarations.

Local agent and certificate control issues must be agreed upon in advance. Medical device exporters often overlook the authorized representative's control over the certificate. If the local agent is uncooperative, the company cannot make changes, update labels, or renew the certificate during its validity period, which may threaten market supply. It is recommended to explicitly state in the agency agreement that certificate ownership belongs to the company, and the authorized representative has the duty not to abuse control, not to delay notifications, and to assist with renewal. Also establish a contingency plan so that documents can be transferred effectively if the agent needs to be replaced.

For multi-country registration, we recommend a “core technical file package plus country-specific difference files” structure. Comprehensive product description, performance testing, biocompatibility, and quality management system data serve as the base, while one-page difference files are created to address each country's special requirements. This reduces repeated translation, testing, and deficiencies. Companies should assign a dedicated technical file position, managed by personnel familiar with regulations and systems, to maintain all registration file versions and the difference table. Post-market maintenance is equally important: after product launch, design or process changes must be assessed for impact on the registration approval and submitted through the local agent in a timely manner.

Frequently Asked Questions

What test reports are needed to export medical dressings?

Typically, biocompatibility reports per ISO 10993 (cytotoxicity, sensitization, irritation), physical performance test reports (liquid absorption, tensile strength, water vapor transmission rate, etc.), sterilization validation and sterility test reports for sterile dressings, and shelf-life validation reports. Some countries may require additional tests based on local pharmacopeia or standards; confirm with the target-country agent at the project early stage.

Can CE technical documentation be used directly for registration in Southeast Asia?

No, not directly. CE documentation can serve as a foundation, but several localization adjustments are needed. First, the classification may differ: the same dressing may have a different classification under CE versus a Southeast Asian country, changing the technical file structure and review focus. Second, the clinical evaluation section may need local population data or clinical database references. Third, labels and instructions must be translated into the local language and comply with local regulations. Finally, some countries require additional chemical or stability reports, so a gap analysis should be performed in advance.

What impact will changing the local agent during the registration process have?

Changing agents affects the transfer of registration documents and control of the registration certificate. If the original agent is uncooperative, deficiency notices or renewal information may not be obtained in time. The new agent must reconfirm the authorization letter format and may need to provide a new local registered address and quality system declaration. During the transition, the regulatory authority may suspend review of the technical file or require re-notarization of authorization documents. It is prudent to select a reputable agent from the start and clearly specify certificate ownership and transfer assistance obligations in the contract.